جميع الدراسات
التوظيفاستكشاف علاجي (المرحلة الثانية)تداخلي

A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B (PRESent-2)

This research study, called PRESent-2, is testing a new medication called SerpinPC. It's for adults with severe haemophilia A or moderately severe to severe haemophilia B. The main goal is to find out if SerpinPC can help reduce the number of bleeding episodes these patients experience, especially those who currently only treat bleeds when they occur (this is called 'on-demand' treatment). Researchers will carefully compare bleeding rates before and after taking SerpinPC. They will also be looking closely at how safe the new medicine is and how it affects people's quality of life. This is a Phase 2 study, meaning it's exploring how well the medicine works and its safety in a smaller group of people.

نظرة سريعة

الحالة
التوظيف
المرحلة
استكشاف علاجي (المرحلة الثانية)
الراعي
Apcintex Limited
الهدف من التسجيل
59
ابدأ
25 Jul 2023

ما هو موضوع هذه الدراسة؟

This research study is looking into a new medicine called SerpinPC for people who have severe haemophilia A or moderately severe to severe haemophilia B. Haemophilia is a condition where your blood doesn't clot properly, which can lead to frequent bleeding, often into joints and muscles. This study wants to see if SerpinPC can make a real difference in reducing these bleeding episodes.

The main thing researchers want to find out is whether SerpinPC can lower how often people who currently treat bleeds as they happen (sometimes called 'on-demand' treatment) actually experience them. They will compare the number of bleeds a person has before starting SerpinPC with the number of bleeds they have while taking the medicine. They're also interested in how safe SerpinPC is and whether it affects people's overall quality of life.

This is an important step in finding new ways to help people living with haemophilia. If SerpinPC proves to be effective and safe, it could offer a new treatment option for managing bleeding and improving daily life for those with the condition.

النقاط الرئيسية

  • This study is testing a new medicine called SerpinPC for people with severe haemophilia A or B.
  • The main goal is to see if SerpinPC can reduce bleeding episodes.
  • It's a Phase 2 study, focusing on how well the medicine works and its safety.
  • Participants will have regular clinic visits, blood tests, and health checks.
  • يمكنك التوقف عن المشاركة في أي وقت.
  • The study is for adult men aged 18 and over.

من قد يكون مؤهلاً؟

To take part in this study, you need to be an adult, aged 18 or older. The study is specifically for men.

You must have been diagnosed with severe haemophilia A or moderately severe to severe haemophilia B. These are specific types of haemophilia that the study is focusing on.

There might be other health requirements or medications you are taking that would mean you couldn't join, but these would be discussed with you in detail by the study team.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. هل عمرك 18 سنة أو أكثر؟
  2. هل أنت رجل؟
  3. Do you have severe haemophilia A?
  4. Or do you have moderately severe to severe haemophilia B?
  5. Are you currently treating bleeds only when they happen ('on-demand')?
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you decide to take part in this study, you would first have a screening visit to make sure it's suitable for you. After that, there will be an observation period where your usual medical care and bleeding episodes would be recorded. Then, you would start taking the study medicine, SerpinPC, regularly for a period.

The study involves regular visits to the clinic where you would have blood tests, physical examinations, and answer questions about your health and any bleeding episodes. You would also track any bleeds and possibly fill out questionnaires about how you are feeling and your quality of life. The study plans to look into your health up to 24 weeks after you start taking SerpinPC. The total duration of your involvement could be longer, depending on how the study progresses, but you would be given full details of the schedule.

المخاطر والفوائد المحتملة

Taking part in a clinical study means you might get access to a new treatment before it's widely available, which could potentially reduce your bleeding episodes if SerpinPC works well for you. However, there's no guarantee the treatment will be effective, and you might not experience any direct benefit. All medicines have potential side effects, and SerpinPC could have risks that are not yet fully known. The study team will closely monitor your health to identify any issues quickly. Remember, joining is entirely voluntary, and you are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

المواقع (7)

بعض مواقع الأماكن تقريبية. نحن نعمل على تحسين ذلك — يرجى التحقق مع فريق التجربة قبل السفر.
  • —
    غير مؤكد
    إسبانيا
  • —
    غير مؤكد
    ألمانيا
  • —
    غير مؤكد
    بلجيكا
  • —
    غير مؤكد
    إيطاليا
  • —
    غير مؤكد
    فرنسا
  • —
    غير مؤكد
    بولندا
  • —
    غير مؤكد
    بلغاريا

أسئلة شائعة

What is haemophilia?

Haemophilia is a genetic condition where your blood doesn't clot properly, leading to longer bleeding and easy bruising.

What is SerpinPC?

SerpinPC is the name of the investigational medicine being tested in this study for treating haemophilia.

What does 'on-demand' treatment mean?

On-demand treatment means you only take medicine to stop bleeding once it has already started, rather than regularly to prevent it.

Will I know if I'm getting SerpinPC?

This is an 'open-label' study, which means both you and your study doctor will know that you are receiving SerpinPC.

كم ستستغرق الدراسة بالنسبة لي؟

The main part of the study where your bleeds are assessed will last up to 24 weeks after you start SerpinPC, but your total involvement could be longer.

كيفية معرفة المزيد

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

هل أنت مهتم بالمشاركة؟

سجل اهتمامك

شارك تفاصيلك وفريق البحث لـ "A Global, Open-label, Adaptive Design Study to Investigate t… "سيتواصل معك إذا كنت مؤهلاً. تحدث دائمًا إلى طبيبك قبل الموافقة على المشاركة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.